Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Prime Medicine, Inc. Common Stock (PRME)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: PRME (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $8.39
1 Year Target Price $8.39
| 6 | Strong Buy |
| 2 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.26% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 317.73M USD | Price to earnings Ratio - | 1Y Target Price 8.39 |
Price to earnings Ratio - | 1Y Target Price 8.39 | ||
Volume (30-day avg) 12 | Beta 1.55 | 52 Weeks Range 1.11 - 6.75 | Updated Date 06/29/2025 |
52 Weeks Range 1.11 - 6.75 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3603.3% |
Management Effectiveness
Return on Assets (TTM) -40.36% | Return on Equity (TTM) -115.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 294627578 | Price to Sales(TTM) 82.61 |
Enterprise Value 294627578 | Price to Sales(TTM) 82.61 | ||
Enterprise Value to Revenue 76.61 | Enterprise Value to EBITDA -3.1 | Shares Outstanding 131294000 | Shares Floating 60489163 |
Shares Outstanding 131294000 | Shares Floating 60489163 | ||
Percent Insiders 24.21 | Percent Institutions 56.84 |
Analyst Ratings
Rating 4 | Target Price 8.39 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Prime Medicine, Inc. Common Stock
Company Overview
History and Background
Prime Medicine, Inc. was founded in 2020 and is focused on developing Prime Editing therapies, a next-generation gene editing technology. It aims to create potentially curative gene editing therapies for a wide range of diseases. It went public in 2022.
Core Business Areas
- Gene Editing Therapeutics: Prime Medicine is focused on developing Prime Editing therapies, a next-generation gene editing technology which directly edits genes at a specific location in the genome.
Leadership and Structure
Prime Medicine is led by CEO Keith Gottesdiener. The organizational structure consists of research and development, clinical development, and corporate functions.
Top Products and Market Share
Key Offerings
- Prime Editing Technology Platform: Prime Editing is the key offering, a gene editing technology to directly edit genes at a specific location in the genome with high precision. Currently, it is in preclinical development. No revenue data is currently available. Competitors include companies focused on CRISPR-based gene editing, such as CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics.
Market Dynamics
Industry Overview
The gene editing industry is rapidly evolving, with significant investment and innovation focused on developing curative therapies for genetic diseases. Key drivers include technological advancements, increasing prevalence of genetic disorders, and regulatory support for gene therapy development.
Positioning
Prime Medicine is positioned as a leader in Prime Editing technology, which aims to offer advantages over earlier gene editing approaches like CRISPR-Cas9. Its competitive advantage lies in the theoretical increased precision and reduced off-target effects of Prime Editing.
Total Addressable Market (TAM)
The total addressable market for gene editing therapies is estimated to be in the tens of billions of dollars. Prime Medicine is positioned to capture a share of this market by developing Prime Editing therapies for various genetic diseases. Specific target markets include liver diseases, eye diseases, and hematologic disorders.
Upturn SWOT Analysis
Strengths
- Proprietary Prime Editing technology
- Strong intellectual property portfolio
- Experienced leadership team
- Significant funding and strategic partnerships
Weaknesses
- Early stage of development (preclinical)
- High development costs
- Regulatory hurdles
- Reliance on Prime Editing technology
Opportunities
- Expanding Prime Editing platform to new diseases
- Partnerships with pharmaceutical companies
- Advancements in delivery technologies
- Positive clinical trial results
Threats
- Competition from other gene editing technologies (e.g., CRISPR)
- Adverse events in clinical trials
- Changes in regulatory landscape
- Patent disputes
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- NTLA
Competitive Landscape
Prime Medicine competes with other gene editing companies, particularly those using CRISPR technology. Its key advantage is Prime Editing, but it faces the challenge of proving its superiority in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Prime Medicine's historical growth is measured by the progress of its Prime Editing platform and expansion of its pipeline.
Future Projections: Future growth projections depend on clinical trial success and regulatory approvals. Analyst estimates will vary widely depending on perceived probabilities of success.
Recent Initiatives: Recent initiatives include advancing preclinical programs, expanding partnerships, and strengthening the intellectual property portfolio.
Summary
Prime Medicine is a promising gene editing company focused on Prime Editing, with a potential advantage over CRISPR. It faces challenges with early-stage development and competition. Clinical trial successes and strategic partnerships are crucial for its growth. Investment hinges on the potential of Prime Editing and its ability to differentiate itself within the gene editing landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Press Releases
- Company Website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prime Medicine, Inc. Common Stock
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2022-10-20 | CEO & Director Dr. Allan Reine M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 214 | Website https://primemedicine.com |
Full time employees 214 | Website https://primemedicine.com | ||
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.